Litcius/Paper detail

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study

Robert P. McMahon, Sebastian Toepfer, Natascha Sattler, Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, Romana Hochreiter, Karin Kosulin, Robert M. Mader, Oliver Zoihsl, Nina Wressnigg, Katrin Dubischar, Vera Buerger, Susanne Eder-Lingelbach, Juan-Carlos Jaramillo

2024The Lancet Infectious Diseases41 citationsDOI

Topics & Concepts

ChikungunyaPersistence (discontinuity)MedicineVirologyAttenuated vaccineAntibodyChikungunya feverAdministration (probate law)ImmunologyVirusBiologyGeneticsVirulenceEngineeringGeneGeotechnical engineeringLawPolitical scienceMosquito-borne diseases and controlViral Infections and Outbreaks ResearchBiological Research and Disease Studies
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study | Litcius